SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:umu-198495"
 

Sökning: id:"swepub:oai:DiVA.org:umu-198495" > ANGPTL4 silencing v...

ANGPTL4 silencing via antisense oligonucleotides reduces plasma triglycerides and glucose in mice without causing lymphadenopathy

Deng, Mingjuan (författare)
Nutrition, Metabolism and Genomics Group, Division of Human Nutrition and Health, Wageningen University, Wageningen, Netherlands
Kutrolli, Elda (författare)
Lipigon Pharmaceuticals AB, Umeå, Sweden
Sadewasser, Anne (författare)
Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany
visa fler...
Michel, Sven (författare)
Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany
Joibari, Masoumeh Motamedi (författare)
Lipigon Pharmaceuticals AB, Umeå, Sweden
Jaschinski, Frank (författare)
Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany
Olivecrona, Gunilla (författare)
Umeå universitet,Fysiologisk kemi,Lipigon Pharmaceuticals AB, Umeå, Sweden
Nilsson, Stefan K. (författare)
Lipigon Pharmaceuticals AB, Umeå, Sweden
Kersten, Sander (författare)
Nutrition, Metabolism and Genomics Group, Division of Human Nutrition and Health, Wageningen University, Wageningen, Netherlands
visa färre...
 (creator_code:org_t)
American Society for Biochemistry and Molecular Biology, 2022
2022
Engelska.
Ingår i: Journal of Lipid Research. - : American Society for Biochemistry and Molecular Biology. - 0022-2275 .- 1539-7262. ; 63:7
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Angiopoietin-like 4 (ANGPTL4) is an important regulator of plasma triglyceride (TG) levels and an attractive pharmacological target for lowering plasma lipids and reducing cardiovascular risk. Here, we aimed to study the efficacy and safety of silencing ANGPTL4 in the livers of mice using hepatocyte-targeting GalNAc-conjugated antisense oligonucleotides (ASOs). Compared with injections with negative control ASO, four injections of two different doses of ANGPTL4 ASO over 2 weeks markedly downregulated ANGPTL4 levels in liver and adipose tissue, which was associated with significantly higher adipose LPL activity and lower plasma TGs in fed and fasted mice, as well as lower plasma glucose levels in fed mice. In separate experiments, injection of two different doses of ANGPTL4 ASO over 20 weeks of high-fat feeding reduced hepatic and adipose ANGPTL4 levels but did not trigger mesenteric lymphadenopathy, an acute phase response, chylous ascites, or any other pathological phenotypes. Compared with mice injected with negative control ASO, mice injected with ANGPTL4 ASO showed reduced food intake, reduced weight gain, and improved glucose tolerance. In addition, they exhibited lower plasma TGs, total cholesterol, LDL-C, glucose, serum amyloid A, and liver TG levels. By contrast, no significant difference in plasma alanine aminotransferase activity was observed. Overall, these data suggest that ASOs targeting ANGPTL4 effectively reduce plasma TG levels in mice without raising major safety concerns.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinsk bioteknologi -- Medicinsk bioteknologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Medical Biotechnology -- Medical Biotechnology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Mikrobiologi inom det medicinska området (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Microbiology in the medical area (hsv//eng)

Nyckelord

adipose tissue
angiopoietin-like 4
antisense oligonucleotides
fasting
high-fat diet
lipase/ lipoprotein
lipoproteins/metabolism
liver
triglycerides

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy